Sound waves plus immunotherapy: a new hope for hard-to-treat cancers?
NCT ID NCT06524570
First seen Feb 21, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This early-stage study tests whether combining a focused ultrasound treatment (histotripsy) with standard immunotherapy drugs (ipilimumab and nivolumab) is safe and tolerable for people with advanced cancer that has not responded to other treatments. About 24 adults with metastatic or unresectable cancer will receive one session of ultrasound to a tumor while continuing immunotherapy. The goal is to see if this approach can boost the immune system's ability to fight cancer without causing severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Center Utrecht
RECRUITINGUtrecht, Utrecht, Netherlands
Contact
Conditions
Explore the condition pages connected to this study.